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Background:  A clinical  trial conducted  in  India  suggests  that the  oral  cholera  vaccine,  Shanchol,  provides
65%  protection  over  ﬁve  years  against  clinically-signiﬁcant  cholera.  Although  the vaccine  is  efﬁcacious
when  tested  in  an experimental  setting,  policymakers  are  more  likely  to  use  this  vaccine  after  receiving
evidence  demonstrating  protection  when  delivered  to  communities  using  local  health  department  staff,
cold chain  equipment,  and logistics.
Methods:  We  used  a test-negative,  case-control  design  to evaluate  the  effectiveness  of a  vaccination  cam-
paign  using  Shanchol  and  validated  the  results  using  a cohort  approach  that  addressed  disparities  in
healthcare  seeking  behavior.  The  campaign  was  conducted  by  the  local  health  department  using  existing
resources  in  a cholera-endemic  area  of Puri  District,  Odisha  State,  India.  All  non-pregnant  residents  one
year of  age  and  older  were  offered  vaccine.  Over  the next  two years,  residents  seeking  care  for  diarrhea
at  one  of  ﬁve  health  facilities  were  asked  to enroll  following  informed  consent.  Cases  were  patients  seek-
ing  treatment  for  laboratory-conﬁrmed  V.  cholera-associated  diarrhea.  Controls  were  patients  seeking
treatment  for V.  cholerae  negative  diarrhea.
Results:  Of  51,488  eligible  residents,  31,552  individuals  received  one  dose  and  23,751  residents  received
two  vaccine  doses.  We  identiﬁed  44  V.  cholerae  O1-associated  cases  and  366 non  V. cholerae  diarrhea
controls.  The  adjusted  protective  effectiveness  for  persons  receiving  two  doses  was  69.0%  (95%  CI: 14.5%
to  88.8%),  which  is  similar  to the  adjusted  estimates  obtained  from  the  cohort  approach.  A  statistical
trend  test  suggested  a single  dose  provided  a modicum  of  protection  (33%,  test for  trend,  p =  0.0091).
Conclusion:  This  vaccine  was  found  to  be as  efﬁcacious  as the  results  reported  from  a clinical  trial  when
administered  to  a rural  population  using  local  health  personnel  and resources.  This  study  provides  evi-
dence  that  this  vaccine  should  be widely  deployed  by public  health  departments  in  cholera  endemic
areas.
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1. Introduction
Vaccine efﬁcacy is measured using randomized, placebo-
controlled clinical trials. Such studies are usually completed under
ideal conditions where, among other criteria, healthy volunteers
are enrolled, age restrictions and the cold chain are ﬁnely main-
tained, and the vast majority of subjects receive all scheduled doses.
For these experimental studies, the estimated protective effect may
be superior to that obtained when vaccine is administered under
real-life conditions where vaccinees may  suffer from undiagnosed
diseases or a controlled temperature chain may be difﬁcult to main-
tain.
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Given the above situation, policymakers may  request a study
f vaccine effectiveness when the vaccine is delivered to popu-
ations using locally-available personnel and resources in rural
reas or urban slums. To provide this information, we previously
xplored and reported on the operational feasibility of an oral
holera vaccine campaign using Shanchol, a licensed and World
ealth Organization (WHO) prequaliﬁed vaccine [1]. The campaign
as conducted using local staff, cold chain equipment, and logistics
n Satyabadi Block, Odisha State, India, which is a cholera endemic
rea. The aim of this study was to assess the effectiveness of this
accine under these circumstances to prevent clinically-signiﬁcant
holera.
. Methods
.1. Ethical review
The study protocol was approved by the Department of Health
nd Family Welfare, State Government of Odisha; the Human Eth-
cal Committee of the Regional Medical Research Center (RMRC)
n Bhubaneswar, Odisha; the Health Ministry Screening Commit-
ee, Government of India; and the Institutional Review Board of
he International Vaccine Institute in Seoul, Korea. Trained and
upervised interviewers obtained verbal informed consent using
 scripted and pretested message from diarrhea patients 18 years
nd older and from guardians of patients aged 1 to 17 years
f age. Assent was also obtained from patients 12 to 17 years
ld. Participation or refusal to participate was recorded for each
atient.
.2. Study site
As described in detail earlier [1], this study was conducted in
atyabadi Block in Puri District, near the eastern coastal area of
disha State. Satyabadi Block is a cholera endemic area [1–3]. The
tate’s infant mortality rate was 61 per 1000 live births in 2010 [4]
nd literacy was 91% and 78% for males and females, respectively,
n 2011. The study site in Satyabadi Block includes 145 villages
nd hamlets encompassing approximately 50,000 residents (Fig. 1).
emperatures in summer months, March to June, average 37 ◦C [5].
o enumerate the study site, a de jure census was carried out from 9
ebruary to 2 April 2011 to enumerate the regular residents of the
tudy area, map  households, assign unique identiﬁcations numbers
o each individual, assess household socioeconomic, water-use,
anitation, and hygiene characteristics.
.3. Study design
To measure cholera vaccine effectiveness, we conducted a case-
ontrol study using a test-negative design [6–10]. Under this
esign, study participants were residents who sought care for acute
iarrhea. All of these patients were tested for the infection of inter-
st and assigned as pathogen positive cases or pathogen negative
ontrols. Vaccine effectiveness was estimated from the ratio of the
dds of vaccination among subjects testing positive to the odds of
accination among subjects testing negative.
To validate the results obtained from the test-negative design,
e also calculated vaccine effectiveness using a cohort approach.
sing all residents in the study area, the protective effectiveness
as estimated as the ratio of the relative risk of cholera between
accinated and unvaccinated subjects. Since effectiveness in this
pproach may  be inﬂuenced by differential health seeking behavior
etween vaccinated and un-vaccinated subjects (e.g., if vaccinated
ubjects were more likely to seek care), we measured the effec-
iveness after adjusting for the differential health seeking behavior
etween the two groups.33 (2015) 2463–2469
To assess whether effectiveness estimates could be attributed
to study design bias, cases that are positive for a disease that
should not be protected by the vaccine (e.g., Shigella infection)
were compared to pathogen negatives. This design is also called a
bias-indicator study [11,12]. An absence of vaccine protection from
Shanchol in this analysis would provide additional evidence of an
absence of bias in the study design and analysis.
2.4. Vaccine and vaccination
Single dose vials were provided by the manufacturer (Lot no:
SCN006A11, Shantha Biotechnics, Hyderabad, India). Each dose of
the modiﬁed killed bivalent whole-cell vaccine (Shanchol) con-
tained 600 ELISA units of lipopolysaccharide of formalin-killed V.
cholerae O1 El Tor Inaba (strain Phil 6973), 300 ELISA units of
lipopolysaccharide of heat-killed V. cholerae O1  classical Ogawa
(strain Cairo 50), 300 ELISA units of lipopolysaccharide of formalin-
killed V. cholerae O1 classical Ogawa (strain Cairo 50), 300 ELISA
units of lipopolysaccharide of heat-killed V. cholerae O1 classical
Inaba (strain Cairo 48), and 600 ELISA units of lipopolysaccharide
of formalin-killed V. cholerae O139 (strain 4260B). Two  doses were
given at least 14 days apart. Individual vaccine doses were offered
as per directions of the manufacturer. The vaccine cold chain was
maintained as described earlier [1].
The vaccine was  administered during a mass campaign held
from 5 May  to 25 June 2011 [1]. Ambient temperature during the
campaign reached up to 42 ◦C on vaccination days. Vaccines were
transported in temperature controlled vehicles from Hyderabad,
the capital city of Andhra Pradesh to Bhubaneswar, the capital city
of Odisha State and stored in a walk-in-cold room at 2 to 8 ◦C. Vac-
cines were distributed from the cold room to the vaccination sites
on a daily basis throughout the campaign. Sixty-two vaccination
booths, staffed by 395 trained health workers and volunteers pro-
vided vaccine. All healthy, non-pregnant women, one year of age
and older were invited to participate. Pregnancy was ascertained
by verbal screening using dates of last menstrual period.
A vaccination registry contained pre-printed information for
each participant. The information was  obtained during the census
survey. This registry was also used to record dosing. A vaccination
card was  issued to each participant at the time of administra-
tion of the ﬁrst dose. Each participant was requested to bring the
vaccination card at the time of second dose administration. The
information from the vaccination record book was doubly entered
into a password-protected data system (Microsoft Visual FoxPro
7.0).
2.5. Post vaccination surveillance
We  implemented surveillance for study site residents who  pre-
sented to public treatment facilities with diarrhea. The facilities
included two  primary health care centers (i.e., Alagum and Sukala
PHC) and Sakhigopal Area Hospital in Satyabadi Block and the Infec-
tious Disease Hospital and pediatric ward of District Headquarter
Hospital located adjacent to Satyabadi Block in Puri District. The
three local health facilities are marked in Fig. 1.
A diarrhea episode was deﬁned as passage of three or more
loose or liquid stools in any 24-h period within three days before
presentation or one or two  loose/liquid stools with any signs of
dehydration according to WHO  guidelines [13]. This deﬁnition was
the same as that used in the ﬁve-year efﬁcacy trial of Shanchol con-
ducted in Kolkata, India [14]. Patients’ information was  recorded in
a structured questionnaire on a personnel digital assistant (PDA).
Subsequent to the interview, a rectal swab was collected. Treatment
was provided in accordance with national guidelines.
T.F. Wierzba et al. / Vaccine 33 (2015) 2463–2469 2465
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.6. Laboratory conﬁrmation
A rectal swab was obtained from each enrolled diarrhea patient,
laced in capped tube containing Cary-Blair transport media, and
ransported at room temperature to the laboratory of the Regional
edical Research Center in Bhubaneswar. The sample reached the
aboratory within 6 to 8 h. Standard methods were used for isolation
f V. cholerae and Shigella [15]. For V. cholerea, the swab was  plated
nto Eiken thiosulfate citrate bile salt sucrose (TCBS) agar directly
s well as after enrichment in alkaline peptone water (APW) for 4 to
 h at 37 ◦C and pH 8.6. After overnight incubation, morphologically
uspected colonies were tested biochemically and agglutinated
ith O1 polyvalent, Ogawa and Inaba antisera. Non-agglutinating
trains were tested with antiserum to V. cholerae O139 strain.
he O1 isolates were further biotyped with chicken erythrocyte
gglutination tests, Voges-Proskauer test and with determination
f polymyxin susceptibility [16]. The genes for ctxB Classical or
l Tor were determined using the mismatch ampliﬁcation muta-
ion assay (MAMA) polymerase chain reaction [17,18]. For Shigella
solation, the rectal swab was plated onto MacConkey (MAC) agar
nd Hektoen enteric (HE) agar. After 18 to 24 h incubation at 37 ◦C,
uspected colonies were tested biochemically for identiﬁcation of
higella spp. Once Shigella was conﬁrmed, slide agglutination tests
ere performed to classify by serogroup: S. dysenteriae, S. ﬂexneri,
. boydii,  and S. sonnei.
.7. Cases and controls
Diarrhea patients were study site residents who  sought treat-
ent at one of ﬁve health care facilities, met  the deﬁnition of
iarrhea, gave informed consent, were listed in the census database,
nd submitted a fecal specimen. Cases were patients found positive
or V. cholerae infection. Controls were diarrhea patients nega-
ive for V. cholerae infection. As cholera infection does not occur
hroughout the year, controls were selected only during the length
f the cholera season as determined by monthly case distribution,he study area of Satyabadi Block, Puri District, Odisha State, India.
that is, from 22 April to 19 October 2013 and 31 March to 10 April
2014.
For the bias-indicator study, cases were diarrhea patients pos-
itive for Shigella spp. and controls were diarrhea patients negative
for Shigella spp. In the same way that cholera cases were cho-
sen according to the monthly distribution, controls for the Shigella
analysis were selected from 14 April to 16 December 2013 and 29
January to 22 April 2014.
2.8. Ascertainment of vaccination history
Vaccination history was ascertained by reviewing the electronic
vaccination registry to identify each diarrhea patient within the
study site who was dosed. Each patient was  then classiﬁed into an
ordinal variable for the number of doses received (i.e., 0, 1, or 2
vaccine doses).
2.9. Variable deﬁnitions
Demographic, environmental, and economic variables and dis-
ease severity were measured and compared between cases and
controls. As data suggests that Shanchol is less efﬁcacious in young
children [14], a participant’s age was  calculated as age at vaccina-
tion and categorized as <15 or ≥15 years old. As years of education
is thought to be inversely associated with cholera risk, we catego-
rized heads of household as having <6 or ≥6 six years of education.
Six years was  the median years of education for household heads
as determined during the study census. As we  have done in previ-
ous studies [11,19], socioeconomic status was  deﬁned as persons
owning none vs. one or more of the following luxury items: bicycle,
television or motorbike. For socioeconomic status, we also catego-
rized households as having only one room vs. those with two  or
more rooms. Higher cholera risk is also found among persons hav-
ing inadequate sanitation. Sanitation was deﬁned as persons who
used a constructed latrine compared to those who  used open ﬁeld
for defecation. Access to clean water was deﬁned as those who had
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ap, well, or hand pump water vs. those who used other resources
uch as pond or surface water. As we had noted previously, cholera
ases were more likely to seek care at a distant health care facil-
ty [14], thus we evaluated the proportion of cases and controls
raveling >2.5 vs ≤ 2.5 km to obtain treatment for diarrhea. The
edian distance from a household to the health care facility was
.5 km as determined during the baseline census. Disease severity
as measured as none vs. some or severe based on WHO  criteria
13].
. Analysis
To identify independent variables that were predictive of V.
holerae-associated diarrhea, we calculated the prevalence of each
ariable among cases and controls. We  then obtained a p-value
or the statistical difference, if any, between cases and controls by
tting the variable into a regression model using a logit function
nd employing generalized estimating equations (GEE) [20]. GEE
ere used to adjust for potential nonindependence of observations
btained from diarrhea patients seeking medical care at the same
ealth care facility.
Subsequently, we calculated the crude odds ratio for cholera-
ssociated diarrhea among cases and controls by adding indicator
ariables for vaccine doses (2 doses, 1 dose, vs. 0 doses) to a logis-
ic regression model using GEE as above. To obtain an adjusted
dds ratio for cholera risk, we simultaneously added all inde-
endent variables with p-value less than 0.10 as well as vaccine
oses to a single multivariate model. The adjusted odds ratio was
btained from these models by exponentiating the coefﬁcients
or cholera vaccination. Ninety-ﬁve percent conﬁdence intervals
95% CIs) were calculated using model coefﬁcients and empiri-
al standard errors and exponentiating those results. The percent
djusted vaccine effectiveness was then calculated as one minus
he odds ratio times 100. We  also tested for a simple linear trend
y ordered vaccine doses by adding statistically signiﬁcant covari-
tes and a single ordinal variable for doses to a logistic regression
odel using GEE.
To validate results of the case-control analysis, we  assembled
 cohort of all area residents and followed them post vaccination
hrough the end of study year two. In the cohort analysis, we calcu-
ated the incidence rate for cholera (cases/baseline population) and
on-cholera diarrhea by vaccine dose (i.e., two, one, no dose). We
ssumed that the incidence rate for non-cholera diarrhea would
e the same for persons receiving two, one or no vaccine doses, if
he vaccine had no impact on non-cholera diarrhea (as expected)
nd there was no difference in health care use by vaccine dose. If
e did ﬁnd a difference in incidence of non-cholera diarrhea by
accine dose, then that difference would suggest that there was
n association between vaccine dose and health seeking behavior
nd we needed to adjusted vaccine effectiveness for health seeking
ehavior. The factor for adjustment (f), was calculated by
 = nIRv
nIRO
IRv = incidence rate of non-cholera diarrhea among vaccinees
two-dose recipients); nIRO = incidence rate of non-cholera diar-
hea among non-dose recipients.
Thus, the adjusted protective efﬁcacy (aPE) in cohort approach
as calculated by
PE = 1 −
(
cIRv
cIRO
× f
)
× 100%IRv = incidence rate of cholera among vaccinees; cIRO = incidence
ate of cholera among non-dose recipients.
In the bias indicator analysis, differences between cases and con-
rols as well as crude and adjusted odds ratio were calculated in33 (2015) 2463–2469
the same manner as for the statistical evaluation of anti-V. Cholerae
vaccine.
All tests were two-tailed, and statistical signiﬁcance was set a
p < 0.05. SAS version 9.03 (SAS Institute Inc., North Carolina, USA)
was used for all analyses.
4. Results
In the study area, of 51,488 eligible residents, 31,552 individuals
received at least one dose and 23,751 residents received two doses
of the vaccine. During the ﬁrst study year, there were only four
diarrhea patients infected with V. cholerae and they were excluded
from the study. In the second year, we identiﬁed 44 V. cholerae-
associated cases and 366 V. cholerae-negative diarrhea controls. Of
the 44 cases, 18 received no vaccine, nine received one dose, and 17
received two doses. For controls, 73, 59, and 234 received no, one,
and two vaccine doses, respectively. None of the cases or controls
were reported to have received a partial dose or spit up vaccine.
There were no repeat treatment visits for the same illness. Of  the
44 V. cholerae cases, all were O1 Ogawa of which 34 were El Tor Vari-
ant and 10 were Hybrid (El Tor/Classical) biotypes. Forty patients
among cholera cases and 312 patients among controls were either
some or severely dehydrated yielding no signiﬁcant difference of
the dehydration status between these two  groups (p = 0.24). In con-
trast, we observed a signiﬁcantly higher dehydration (p < 0.0001)
for the bias indicator study (Shigella versus non-Shigella).
The cholera cases and controls were comparable for most pop-
ulation characteristics (Table 1). Still, cases were less likely to be
under 15 years of age than controls (15.9% vs. 27.0%, p = 0.0011) and
cases were more likely to have traveled further than 2.5 km to seek
health care than controls (47.7 vs. 27.0, p = 0.0012). The adjusted
vaccine effectiveness for residents who  received two  doses com-
pared to those who received no vaccine was 69.0% (95% CI: 14.5%
to 88.8%) (Table 2). Residents who received only one dose had 32.5%
(95% CI: −318.0% to 89.1%) protection but this was not statisti-
cally signiﬁcant. However, a trend test for effectiveness by dose
was statistically signiﬁcant (p = 0.0091)
For the bias indicator analysis, there were 19 laboratory-
conﬁrmed Shigella-associated cases and 606 non-Shigella cases
(Tables 1 and 2). Among the Shigella positive cases, 16 were
S. ﬂexneri,  two were S. boydii,  and one S. dysenteriae. Shigella-
associated cases were more likely to be male than female, (73.7% vs.
57.7%, p < 0.0001) and to reside further from a health care facility
(57.9% vs. 31.0%, p = 0.0012). There was no statistically signiﬁcant
association between Shigella risk and cholera vaccine doses. The
trend test by dose was  not statistically signiﬁcant (p = 0.98).
In cohort analysis, we observed the incidence rate of non-
cholera diarrhea among two-dose recipients was 2.7 times higher
than that among non-dose recipients (Table 3), which indicates het-
erogeneity in healthcare seeking behavior between vaccinees and
non-vaccinees in that setting. This had led to a very low protective
efﬁcacy when performing a classical analysis (21%; 95% CI:—54–59;
p = 0.49). We,  therefore, calculated the adjusted incidence rate of
cholera after controlling for the health seeking behavior, which
yielded 2.42/100,000 population, and provided 70% protective
effectiveness (95% CI: 48–83; p < 0.0001).
5. Discussion
A controlled clinical trial conducted in Kolkata, India suggests
that Shanchol, a locally-licensed, WHO-prequaliﬁed oral cholera
vaccine, provides 65% protection against clinically-signiﬁcant
cholera over ﬁve years. To evaluate the feasibility of deploying this
vaccine in a non-experimental setting, we conducted and previ-
ously reported on a vaccine campaign with Shanchol using local
government health personnel and infrastructure in a rural cholera
T.F. Wierzba et al. / Vaccine 33 (2015) 2463–2469 2467
Table  1
Socio-demographic characteristics and disease severity of Cholera cases, Shigella cases, and controls.
Cholera (n = 44) Controls (n = 366) p Value Shigella (n = 19) Controls (n = 606) p Value
No. % No. % No. % No. %
Male 21 47.7 187 51.1 0.129 14 73.7 313 51.7 <0.0001
Age  at vaccination (May 5, 2011) <15 years 7 15.9 99 27.0 0.001 6 31.6 160 26.4 0.108
Household head had six years of education or
less
32 72.7 279 76.2 0.646 17 89.5 460 75.9 0.160
Only  one room in house 14 31.8 103 28.0 0.510 7 36.8 175 28.9 0.506
Own  bicycle, television, or motorbike 34 77.3 281 76.8 0.953 15 78.9 471 77.7 0.935
Use  open ﬁeld as toilet 40 90.9 325 88.8 0.543 19 100.0 545 89.9 –
Use  own tap, well, or hand pump water 8 18.2 42 11.5 0.082 1 5.3 77 12.7 0.089
Longer than median distance from the
household to the nearest health facility
(>2.5 km)
21 47.7 99 27.0 0.001 11 57.9 188 31.0 0.001
Some  to severe dehydration 40 90.9 312 85.2 0.239 18 94.7 505 83.3 <0.0001
Table 2
Dose response effectiveness of the Shanchol vaccine against clinical cholera and Shigellosis in a rural area of India, 2013–2014.
Outcome Vaccination status Cases Controls Odds Crude odds ratio (95%CI) Adjusted odds ratioa (95%CI) % Vaccine effectiveness (95% CI)
Cholera 0 dose 18 73 0.25 1 1
1  dose 9 59 0.15 0.605 (0.116, 3.157) 0.675 (0.109, 4.180) 32.5 (−318.0, 89.1)
2  doses 17 234 0.07 0.287 (0.110, 0.749) 0.310 (0.112, 0.855) 69.0 (14.5, 88.8)
Shigella 0  dose 5 135 0.04 1 1
1  dose 2 104 0.02 0.568 (0.092, 3.498) 0.604 (0.098, 3.733) 39.6 (−273.3, 90.2)
2  doses 12 367 0.03 0.951 (0.328, 2.758) 1.106 (0.384, 3.183) −10.6 (−218.3, 61.6)
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a For cholera, results are adjusted for age at vaccination, sex, and distance to the ne
endemic area of India [1]. The campaign included almost 400 gov-
rnment health workers (with one days training) and volunteers
orking at 62 vaccination posts placed throughout the area of
lmost 52,000 residents. From May  to June 2011, the hottest sea-
on of the year, non-pregnant residents one year of age and above
ere offered two vaccine doses, 14 days apart. Sixty-one percent of
he population received one or two vaccine doses. Despite the dif-
cult circumstances, the investigators from that study concluded
hat the vaccine campaign was realistic and affordable.
In this study, we present ﬁndings assessing the effectiveness of
his oral cholera vaccine campaign to prevent clinically-signiﬁcant
holera. Our results suggest that the vaccination campaign was suc-
essful. More than two in three vaccinees receiving two vaccine
oses were protected from clinically signiﬁcant cholera. The results
f our study also hinted that one dose reduces severe cholera cases
y nearly one-third. A study conducted in Zanzibar using Dukoral,
 product similar to Shanchol [11], and an effectiveness study in
uinea of persons who received incomplete vaccination (i.e., one
ose or if one or both dose spat out or vomited [21]) demonstrated
imilar levels of protection for a single dose. Combined, these data
uggest that there is a protective beneﬁt from a single vaccine dose.
We believe these results to be robust. Since we consid-
red all diarrheal patients coming from our study area to the
able 3
ncidence rate for cholera and non-cholera diarrhea and protective efﬁcacy of the vaccine
Outcome Vaccination status Population Cases
Cholera 0 dose 19,936 18 
1  dose 7801 9 
2  doses 23, 751 17 
Non-cholera diarrhea 0 dose 19,936 73 
1  dose 7,801 59 
2  doses 23,751 234 
* The adjustment was made considering that vaccinees (2-dose recipients) and non-va
ehavior had been same for both the groups. And, in that case, the incidence rate of cholera
fﬁcacy  is calculated by (1 − 0.72/2.42) × 100%.rsely associated (p = 0.0091), but vaccine dose is not associated (p = 0.9833) with
 health facility and for Shigella, adjusted for the same variables plus disease severity.
treatment sites, the test-negative design minimized the effects
of healthcare seeking behavior on vaccine effectiveness. This
is in contrast to the results we  observed using in the cohort
analysis. Our analysis also indicates that classical way of evalu-
ating vaccine effectiveness using cohort or case-control models
may  seriously underestimate vaccine effectiveness unless health-
care seeking behavior of the study population are addressed
analytically.
The test-negative design used in this study is predicated on
the assumption that the intervention has no effect on other non-
targeted etiologies resulting in similar symptomology and there is
high laboratory test speciﬁcity [7]. To the best of our knowledge,
there is no indication that this vaccine would provide protec-
tion against other diarrheal etiologies. And, as our data shows,
we did not detect protection against Shigella-associated infections.
With regards to test speciﬁcity, while bacterial culture is the gold
standard for cholera diagnosis, there is an indication that the
speciﬁcity is marginally lower when compared to diagnostics that
include bacterial culture and polymerase chain reaction methods
[22]. Given this, the estimated effectiveness in this study may  vary
from the true effectiveness. However, this would be the case for
all Shanchol trials and effectiveness studies as PCR have not been
widely used in trials to screen for V. cholerae infection.
 using cohort approach.
Incidence rate/100,000 Protective efﬁcacy (%)
Crude estimate
(95% CI, p-value)
Adjusted estimate∗
(95% CI, p-value)
0.90 – –
1.15 – –
0.72 21 (−54–59; 0.49) 70(48-83; <0.0001)
3.66 – –
7.56 – –
9.85 – –
ccinees would have similar rates for the non-cholera diarrhea, if the health seeking
 among non-vaccinees would have been 2.42/100,000. Thus, the adjusted protective
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There were several other issues to consider when evaluating
he results of our study. Although we validated the test-negative
esign using a cohort analysis which addressed the healthcare
eeking behavior of the study population, this design has not
een validated against the results of randomized controlled trials
f cholera vaccines. Such an analysis would hopefully add addi-
ional credence to our results. Our estimate of vaccine effectiveness
ould be biased if disease severity differed for the vaccinated
nd unvaccinated [23] and affected health-seeking behavior. For
holera, we did not ﬁnd signiﬁcant differences in disease severity
etween the vaccinated and unvaccinated. There is an opportu-
ity for selection bias in studies of vaccine effectiveness if only
 subgroup of all cholera patients are tested for infection. The
est-negative design minimizes this possibility as all patients seek-
ng care for diarrhea and meeting case deﬁnition are cultured for
. cholerae [8,23]. Like other observational study designs, differ-
nce in the risk of disease could bias our estimates if the risk
s not the same for vaccinees and non-vaccinees. We  have tried
o ensure for comparability between groups by including vari-
bles for sanitation and water use into our statistical models and
ave limited our analysis to calendar time when residents were
t risk of cholera. We  were underpowered to detect a statis-
ically signiﬁcant effect from a single dose. However, as noted
arlier, the trend test was signiﬁcant. Still, the question concern-
ng the efﬁcacy of a single vaccine dose will be best answered
y an individually randomized, controlled trial being conducted
n Bangladesh by icddrb and the International Vaccine Institute,
epublic of Korea. We  were unable to present age-speciﬁc esti-
ates for protection as the study was not sufﬁciently powered
or that analysis. However, age-speciﬁc effectiveness has been
bserved in other oral cholera vaccine studies, where protection
n preschool children was less relative to older children and adults
14]. Finally, the analysis of the cohort approach suggest that the
est-negative design is free from bias due to healthcare seeking
ehavior, as the adjusted rate of the cohort approach is similar
o our results. Still, if there is any effect from differential care
eeking behavior by vaccinated and unvaccinated, then our esti-
ates would be considered as conservative as non-vaccinees were
ess likely like to visit in our target hospitals than that by vacci-
ees.
In summary, cholera remains a serious public health problem in
any developing nations. In endemic countries of Asia and Africa,
n estimated 2.8 million cases and 91,000 deaths occur each year
24]. Cholera prevention has been based on provision of safe water,
anitation, and treatment with rehydration therapy and antibi-
tics. In 2012, researchers added to the anti-cholera armamentum
y reporting that a clinical trial in Kolkata, India suggests that an
ral cholera vaccine afforded 65% protection against severe dis-
ase over ﬁve years for non-pregnant residents, one year of age
nd older cholera [14]. That vaccine is now prequaliﬁed, that is,
pproved by the World Health Organization for purchase by United
ations agencies. In 2014, researchers also showed that this vac-
ine offered substantial protection, 86.6%, when used at the onset
f a cholera outbreak in Guinea [21]. In this study, we observed
rotection against clinically-signiﬁcant V. cholerae infection in a
ural, cholera endemic area of India. This study supports the use of
hanchol in government immunization programs and further sug-
ests that the vaccine should be made widely available to health
epartments throughout India as well as other cholera endemic
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